395 research outputs found
effectiveness of myopia control interventions: a systematic review of 12 randomized control trials published between 2019 and 2021
No full textPublisher Copyright: Copyright © 2024 Lanca, Pang and Grzybowski. Errata de: Lança C, Pang CP, Grzybowski A. Effectiveness of myopia control interventions: a systematic review of 12 randomized control trials published between 2019 and 2021. Frontiers in Public Health. 2023;11:1125000. doi: 10.3389/fpubh.2023.1125000. eCollection 2023.[This corrects the article DOI: 10.3389/fpubh.2023.1125000.].publishersversionpublishe
a systematic review of 12 randomized control trials published between 2019 and 2021
No full textPublisher Copyright: Copyright © 2023 Lanca, Pang and Grzybowski. Errata publicada em: Lanca C, Pang CP, Grzybowski A. Corrigendum: Eectiveness of myopia control interventions: a systematic review of 12 randomized control trials published between 2019 and 2021. Front. Public Health. 2024;12:1460156. doi: 10.3389/fpubh.2024.146015Purpose: This study aims to investigate the effectiveness of interventions to control myopia progression. In this systematic review, the primary outcomes were mean differences (MD) between treatment and control groups in myopia progression (D) and axial length (AL) elongation (mm). Results: The following interventions were found to be effective (p < 0.001): highly aspherical lenslets (HAL, 0.80 D, 95% CI, 0.77–0.83; −0.35 mm, 95% CI −0.36 to −0.34), MiSight contact lenses (0.66 D, 95% CI, 0.63–0.69; −0.28 mm, 95% CI −0.29 to −0.27), low dose atropine 0.05% (0.54 D, 95% CI, 0.38–0.70; −0.21 mm, 95% CI-0.28 to −0.14), Biofinity +2.50 D (0.45 D, 95% CI, 0.29, 0.61; −0.24 mm, 95% CI −0.33 to −0.15), defocus incorporated multiple segments [DIMS] (0.44 D, 95% CI, 0.42–0.46; −0.34 mm, 95% CI −0.35 to −0.33) and ortho-k lenses (−0.24 mm, 95% CI −0.33 to −01.5). Conclusion: Low-dose atropine 0.01% was not effective in reducing AL progression in two studies. Treatment efficacy with low-dose atropine of 0.05% showed good efficacy. Spectacles (HAL and DIMS) and contact lenses (MiSight and Biofinity) may confer a comparable treatment benefit compared to atropine, to slow myopia progression.publishersversionpublishersversionpublishe
Ban dao ti wei qiang zhong dian ci ji hua zi liu ti de tu an xing cheng
No full textChan, Ka Pang = 半導體微腔中電磁極化子流體的圖案形成 / 陳家鵬.Thesis M.Phil. Chinese University of Hong Kong 2015.Includes bibliographical references (leaves 168-171).Abstracts also in Chinese.Title from PDF title page (viewed on 30, November, 2016).Chan, Ka Pang = Ban dao ti wei qiang zhong dian ci ji hua zi liu ti de tu an xing cheng / Chen Jiapeng
Editorial: Refractive errors: public health challenges and interventions
No full textFunding Information: The guest editors would like to acknowledge the contributions of all authors and reviewers that made the publication of this Research Topic possible.publishersversionpublishe
Herbal molecules in eye diseases
No full textAbstractThe eyes are exposed to oxidative stress due to light absorption and the high metabolism rate of their tissue cells. Oxidative stress plays an important role in the pathogenesis of many major eye diseases, including ocular inflammation, neovascularization, age-related macular degeneration, glaucoma, and cataracts. Herbal molecules, such as lutein, zeaxanthin, omega-3 fatty acids, vitamin C, and vitamin E, have been tried as ocular aliments. Although there are many positive outcomes for preventive or even therapeutic uses for ocular diseases, the efficacy remains controversial. Nevertheless, traditional Chinese medicine remains the best choice of herbal molecules mining for ocular remedies
Effectiveness of myopia control interventions: A systematic review of 12 randomized control trials published between 2019 and 2021
No full textPurposeThis study aims to investigate the effectiveness of interventions to control myopia progression. In this systematic review, the primary outcomes were mean differences (MD) between treatment and control groups in myopia progression (D) and axial length (AL) elongation (mm).ResultsThe following interventions were found to be effective (p < 0.001): highly aspherical lenslets (HAL, 0.80 D, 95% CI, 0.77–0.83; −0.35 mm, 95% CI −0.36 to −0.34), MiSight contact lenses (0.66 D, 95% CI, 0.63–0.69; −0.28 mm, 95% CI −0.29 to −0.27), low dose atropine 0.05% (0.54 D, 95% CI, 0.38–0.70; −0.21 mm, 95% CI-0.28 to −0.14), Biofinity +2.50 D (0.45 D, 95% CI, 0.29, 0.61; −0.24 mm, 95% CI −0.33 to −0.15), defocus incorporated multiple segments [DIMS] (0.44 D, 95% CI, 0.42–0.46; −0.34 mm, 95% CI −0.35 to −0.33) and ortho-k lenses (−0.24 mm, 95% CI −0.33 to −01.5).ConclusionLow-dose atropine 0.01% was not effective in reducing AL progression in two studies. Treatment efficacy with low-dose atropine of 0.05% showed good efficacy. Spectacles (HAL and DIMS) and contact lenses (MiSight and Biofinity) may confer a comparable treatment benefit compared to atropine, to slow myopia progression
Corrigendum: Effectiveness of myopia control interventions: a systematic review of 12 randomized control trials published between 2019 and 2021
No full text
- …
